Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03411252 · ClinicalTrials.gov registry record · Early Phase 1
Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study
A Early Phase 1 study, sponsored by Thomas Jefferson University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT03411252: Clinical Trial Early Phase 1 study, sponsored by Thomas Jefferson University.
NCT03411252 is a Early Phase 1 study that was terminated before completion, run by Thomas Jefferson University. The registered enrollment target is 5 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03411252, a Early Phase 1 study, was terminated before completion, sponsored by Thomas Jefferson University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study evaluates whether a medication called mirabegron is better than placebo (sugar pill) in helping patients with achalasia swallow better. Each patient will receive either mirabegron or the placebo for 4 weeks followed by the opposite medication. Each patient will complete several surveys and undergo several tests to determine if the mirabegron is helping reduce the pressures in the esophagus (swallowing tube).
Primary Outcome
Evaluation of changes in lower esophageal sphincter pressures using high resolution manometry
Interventions
- DRUG Placebo
- DRUG Mirabegron 50 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-02-15 |
| Est. Completion | 2019-12-15 |
| Phase | Early Phase 1 |
Why NCT03411252 stopped before completion
NCT03411252 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03411252 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03411252 about?
NCT03411252 is a clinical study titled "Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study". This study evaluates whether a medication called mirabegron is better than placebo (sugar pill) in helping patients with achalasia swallow better. Each patient will receive either mirabegron or the placebo for 4 weeks followed by the opposite medication. Each patient will complete several surveys an...
What is the current status of trial NCT03411252?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2018-02-15. Estimated completion is 2019-12-15.
What interventions are being tested in trial NCT03411252?
The interventions under investigation include: Placebo (DRUG), Mirabegron 50 MG (DRUG).
Who is sponsoring clinical trial NCT03411252?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03411252's enrollment target sits among peer trials
5 1887th of 2000 higher than 80 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI